Mrs Tracy Bahakel Laforty, | |
2166 Pelham Parkway, Pelahm, AL 35124 | |
(205) 664-8787 | |
Not Available |
Full Name | Mrs Tracy Bahakel Laforty |
---|---|
Gender | Female |
Speciality | Marriage & Family Therapist |
Location | 2166 Pelham Parkway, Pelahm, Alabama |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1437365418 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
106H00000X | Marriage & Family Therapist | (* (Not Available)) | Secondary |
106H00000X | Marriage & Family Therapist | 362 (Alabama) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Tracy Bahakel Laforty, P.o. Box 88, Pelham, AL 35124 Ph: (205) 664-8787 | Mrs Tracy Bahakel Laforty, 2166 Pelham Parkway, Pelahm, AL 35124 Ph: (205) 664-8787 |
News Archive
Scientists at the Queensland Brain Institute have uncovered a vital clue into how the brain is wired, which could eventually steer research into nervous system disorders such as Parkinson's disease and cognitive disorders including autism.
International Stem Cell Corporation, www.intlstemcell.com, announced today that the United States Patent and Trademark Office has granted ISCO patent number 7,732,202, the first of several pending patents relating to its development of human parthenogenetic Stem Cells. Human parthenogenetic stem cells are a new type of pluripotent stem cell that allows immune matching to potentially solve critical immune rejection problems, and does not involve the ethical issues that surround the use of fertilized human embryos.
According to new research by the Harvey L. Neiman Health Policy Institute, the use of follow-up imaging is significantly less when initial emergency department ultrasound examinations are interpreted by a radiologist than a nonradiologist.
NovaDigm Therapeutics, a company developing innovative immuno-therapeutics and preventative vaccines for fungal and bacterial infections, today announced the initiation of a Phase 2a study evaluating NDV-3A for the reduction of Staphylococcus aureus (S. aureus) colonization in a high-risk population of military trainees.
› Verified 1 days ago